Financial Performance - Q2 FY26 - Conagra's Q2 FY26 organic net sales decreased by 30% compared to the previous year, totaling $2975 million[51, 52, 53] - Adjusted EPS for Q2 FY26 was $045, a decrease of 357% year-over-year[51] - Adjusted operating margin for Q2 FY26 was 113%, a decrease of 406 bps compared to the previous year[51, 54, 55, 57] - For H1 FY26, organic net sales decreased by 19% to $5586 million[51, 76] - Adjusted EPS for H1 FY26 was $085, a decrease of 309% year-over-year[51] Segment Performance - Q2 FY26 - Grocery & Snacks net sales were $1209 million, with a 15% organic net sales decrease[53] - Refrigerated & Frozen net sales were $1251 million, with a 51% organic net sales decrease[53] - International net sales were $230 million, with a 29% organic net sales decrease[53] - Foodservice net sales were $288 million, with a 02% organic net sales increase[53] Key Business Trends - Frozen retail volume sales showed a return to growth on a two-year basis, with a +08% change in Q2 FY26[14, 15] - 90% of frozen products held or gained volume share vs 2 years ago[15] - Conagra's frozen single-serve meals volume share of category was 529% in Q2 FY26, a +05 percentage point change vs 2 years ago[18, 19, 20, 21] - Conagra's frozen vegetables volume % change was +91% vs 2 years ago[22, 23] - Conagra's frozen vegetables volume share of category was 191% in Q2 FY26, a +13 percentage point change vs 2 years ago[24, 25]

Financial Performance - Total revenue for the second quarter of fiscal year 2026 reached $1,558 million, an 18% increase compared to $1,317 million in the second quarter of fiscal year 2025[8] - Adjusted operating income for the second quarter of fiscal year 2026 was $649 million, a 21% increase compared to $538 million in the second quarter of fiscal year 2025[8] - Adjusted diluted EPS for the second quarter of fiscal year 2026 was $1.26, an 11% increase compared to $1.14 in the second quarter of fiscal year 2025[8] - For the six months ended November 30, 2025, total revenue was $3,097.6 million, an 18% increase[35] - For the six months ended November 30, 2025, adjusted operating income was $1,275.7 million, an 18% increase[35] - For the six months ended November 30, 2025, adjusted diluted EPS was $2.48, an 8% increase[35] Revenue Drivers - Management Solutions revenue increased by 21% from $963 million to $1,166 million[11] - PEO & Insurance Solutions revenue increased by 6% from $318 million to $337 million[11] - Interest on Funds Held for Clients increased by 51% from $36 million to $54 million[11] Fiscal Year 2026 Outlook - The company anticipates total revenue growth of 16.5% - 18.5% year-over-year[33] - The company anticipates adjusted diluted EPS growth of 8.5% - 10.5% year-over-year[33]

Lone Tree Plant Refurbishment - The Lone Tree plant refurbishment is a key project to enable a hub-and-spoke mining and processing strategy for i-80 Gold Corp[14] - The refurbishment aims to unlock transformational value by enabling in-house processing of both sulfide and oxide material from three underground operations[21] - The refurbishment project has completed ~30% detailed engineering, suggesting a high level of technical definition and improved accuracy of capital cost estimates[26] - The anticipated processing scenario is expected to increase margins by approximately $1,000 - $1,500/oz Au at Granite Creek and Archimedes, driving free cash flow generation[21] - The refurbishment project is estimated to require ~600,000 direct construction hours, which is relatively low compared to greenfield mining projects with 1M+ construction hours[26] Production and Development Plan - The company aims to become a mid-tier gold producer with a target of producing 500,000 ounces of gold per annum[2] - The company anticipates average annual gold production to exceed 600,000 ounces in Phase 3 (2032E+), incorporating Granite Creek Underground, Archimedes Underground, Lone Tree Autoclave, Cove Underground, Granite Creek Open Pit, and Mineral Point Open Pit[48] - The company expects to secure funding for the recapitalization plan by the end of Q2 2026 or earlier, aligning with the scheduled construction decision for the Lone Tree refurbishment[43] Financials and Risks - The Lone Tree plant refurbishment project has a revised capital expenditure (CAPEX) of $430 million, compared to the 2023 study's $386 million[37] - The company is actively pursuing senior debt and royalty financing options, with due diligence and evaluation underway[43] - The company is considering the sale of the FAD non-core asset, with indicative proposals expected in early 2026[43]

Merger Benefits - The merger of Union Pacific and Norfolk Southern aims to advance America's domestic manufacturing and economic growth[7] - The merger is projected to convert over 2 million annual truckloads from roads to rails[7] - Customers will benefit from a single network, faster routes, and single-line pricing[7] - Approximately 900 net new union jobs are expected to be created to handle volume growth[7] Operational Improvements - The integrated network will include six new premium intermodal lanes, with transit time savings of up to 20 hours on Southern California/Northeast lanes and up to 95 hours on Southern California/Southeast lanes[11] - The merger anticipates carload growth of 425,000 annual carloads in manifest, bulk, and auto, driven by single-line service in underserved markets[12] - The combined company plans a total of $2.1 billion in incremental integration capital to support growth and greater efficiency[16] - The merger expects to reduce 60,000 car-miles, 2,400 handlings, and 4,700 train-miles each day through optimized operating plans[15] Financial Synergies - The merger anticipates up to $2 billion in net revenue EBITDA synergies[20] - The merger anticipates approximately $1 billion in cost synergies[20] - The merger anticipates generating over $12 billion in annual free cash flow by Year 3[20]

Acquisition Overview - BioMarin will acquire Amicus Therapeutics in an all-cash transaction for $14.50 per share, valuing Amicus' equity at approximately $4.8 billion[14] - The purchase price represents a 33% premium to Amicus' closing stock price on December 18, 2025[14] - The transaction is expected to close in Q2 2026, subject to regulatory clearance and approval by Amicus' stockholders[14] Financial Impact - The acquisition is expected to increase BioMarin's long-term revenue CAGR through 2030 and beyond[12] - It is anticipated to be accretive to Non-GAAP Diluted Earnings Per Share (EPS) in the first 12 months after close and substantially accretive beginning in 2027[12, 28] - BioMarin is committed to deleveraging, targeting gross leverage < 2.5x within two years after close[12, 28] - The transaction will be financed through a combination of cash on hand and approximately $3.7 billion of non-convertible debt financing[14] Strategic Rationale - The acquisition expands BioMarin's position as a leader in rare diseases by adding two marketed, high-growth products[4, 12, 28] - BioMarin's global scale and manufacturing capabilities will enable more patients to benefit from Galafold and Pombiliti + Opfolda[12, 28] - The deal diversifies BioMarin's revenue mix and strengthens its commercial portfolio[5, 12, 15] Product Portfolio - Galafold, an oral therapy for Fabry disease, is projected to generate $458 million in revenue in FY'25, with a growth rate of +10-15%[19] - Pombiliti + Opfolda, a two-component therapy for Pompe disease, is projected to generate $70 million in revenue in FY'25, with a growth rate of +50-65%[24]

SentryGlas® Overview - SentryGlas® is an ionoplast interlayer film used in laminated safety glass, offering enhanced safety, clarity, and resilience[11] - It is 100 times stiffer and 5 times more tear-resistant than PVB (Polyvinyl Butyral) interlayers[25] - SentryGlas® provides design optimization, enabling thinner and lighter laminated glass constructions, which reduces the carbon footprint[25] - The interlayer is less moisture-sensitive than other interlayers, offering improved durability[25] - SentryGlas® offers excellent optics, providing the clearest interlayer option[26] Market Segments and Applications - SentryGlas® is used in hurricane glazing to meet large missile impact requirements[29] - It is applied in railings and balustrades, providing edge clarity and post-breakage strength[31] - SentryGlas® is utilized in high-security buildings to improve durability versus polycarbonate and meet bomb blast and bullet-resistant requirements[33] - It is used in facades to increase glass stiffness up to 50°C, reducing deflection under load and enabling thinner glass with less metal support[37] Growth Strategies and Global Trends - The company focuses on direct sales to laminators and provides global technical representatives to support SentryGlas® processing[41] - The company influences building codes and standards and employs downstream marketing to specify SentryGlas®[43] - Global trends such as climate change, rising sea levels, and intense storms create opportunities for SentryGlas® in glass flood barriers and typhoon/cyclone glazing[44] - Increasing workplace and school safety concerns, coupled with urbanization and geopolitical instability, drive demand for SentryGlas® in forced entry bullet resistance (FEBR) and bullet-resistant glazing[44]

1 22 12 1 Forward-Looking Statements and Non-GAAP Financial Measures Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act, such as statements regarding expected cost savings, the optimization of our network through Network 2.0, the planned tax-free full separation of the FedEx Freight business into a new publicly traded company (the "FedEx Freight Spin-Off"), future financial targets, business strategies, man ...

Financial Highlights - BlackBerry's Q3 FY26 revenue reached $141.8 million[8] - The adjusted gross margin was 78%[8] - Non-GAAP earnings per share were $0.05[8] - GAAP net income was $13.7 million[8], marking the third consecutive quarter of GAAP net income[9] - Adjusted EBITDA was $28.7 million[8] - Total ending cash and investments amounted to $377.5 million[8] - Operating cash flow was $17.9 million[8] - Adjusted OPEX was $85.4 million[8] Segment Performance - QNX segment revenue hit a record high of $68.7 million[13], a 10% year-over-year increase[13] - Secure Communications revenue was $67.0 million[15], exceeding guidance[15] and showing sequential growth[15] - Licensing revenue was $6.1 million[16], aligning with guidance[16] Future Outlook - The company projects total revenue of $531-$541 million for the full fiscal year 2026[18]

Business Overview - NANO Nuclear is positioned to capitalize on the global nuclear renaissance driven by the need for reliable baseload energy, energy independence, and climate mandates[10, 11] - Tech leaders are rapidly expanding nuclear capabilities to address power needs, with examples including Microsoft's investment of ~$1.6 billion in the Three Mile Island nuclear power plant and AWS's investment of over $500 million into SMR development with Dominion Energy[13] - Nuclear energy is recognized as an ideal source of baseload power to meet climate goals, with a growing global commitment to triple nuclear capacity by 2050[19] - The company highlights unprecedented bipartisan support for nuclear energy in the U S, citing the ADVANCE Act and executive orders promoting the nuclear power industry[23, 26] KRONOS MMR Technology - KRONOS MMR is differentiated by its high technology readiness level and de-risked reactor design, supported by proven high-temperature gas-cooled reactor (HTGR) design using TRISO fuel[34, 39] - The company believes KRONOS benefited from over $120 million of capital raised by its prior owner to support its development[40] - KRONOS MMR has a 15MWe/45MWt capacity, ideal for data center projects, and is designed to benefit from economies of scale through modularity and factory production[41] - The company expects to submit a construction permit application to the NRC in Q1 2026, and KRONOS MMR was the first microreactor to enter the Canadian Nuclear Safety Commission's (CNSC) Phase 1 licensing process[42] Financial Performance - Cash and cash equivalents ended FY 2025 at $203.3 million, increasing by ~$175 million from the end of FY 2024, driven by net proceeds from private placements and a follow-on offering[77] - Following an October 2025 private placement, NANO Nuclear's cash position totaled ~$580 million[77] - FY 2025 net loss of $40.1 million increased by ~$30 million year-over-year, primarily due to an increase in R&D and G&A expenses[78] - FY 2025 loss from operations increased to $46.2 million, driven by an ~$23 million increase in G&A and an ~$12 million increase in R&D[71, 76]

Company Overview - KB Home has built approximately 700,000 homes since its founding in 1957[5] - The company operates in 49 major markets across 9 states[8] - KB Home has returned over $1.9 billion to stockholders through repurchases and dividends since Q3 2021[11] Q4 2025 Financial Highlights - Housing revenues totaled $1.68 billion, a decrease of 16% compared to $1.99 billion in Q4 2024[52] - Deliveries decreased by 9% to 3,619 homes, compared to 3,978 homes in Q4 2024[52] - The average selling price decreased by 7% to $465,600, compared to $501,000 in Q4 2024[52] - Net orders decreased by 10% to 2,414, compared to 2,688 in Q4 2024[52] - Backlog value decreased by 37% to $1.40 billion, compared to $2.24 billion in Q4 2024[52] - Book value per share increased 10% to $61.75[52] Capital Allocation and Balance Sheet - The company repurchased approximately 1.6 million shares of its outstanding common stock at a total cost of $100 million during the quarter[52] - Total liquidity was $1.4 billion, including $228.6 million of cash and cash equivalents and nearly $1.2 billion of available capacity under the company's unsecured revolving credit facility[52] - Share repurchases totaled $538 million in 2025[41]